Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norepinephrine Boluses for Prevention of Postreperfusion Syndrome in LDLT
NCT03773276Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Countries
- 1
- Sponsor
- Mansoura University
- Modality
- Small Molecules
- Drugs
- norepinephrine
- Conditions
- Post-reperfusion syndrome (PRS)
01
Overview
Phase 2, open-label, single-arm trial of norepinephrine in Post-reperfusion syndrome (PRS), sponsored by Mansoura University. Primary endpoint: Incidence of postreperfusion syndrome. Started Dec 2018; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Norepinephrine boluses
Patients receive Norepinephrine boluses during portal vein declamping to maintain mABP
03
Who it enrols
Patients undergoing living donor liver transplantation with right lobe graft. Excludes acute fulminant hepatitis, chronic hypertension, moderate/severe valvular heart disease, CKD, hepatorenal syndrome, preoperative serum creatinine > 1.4 mg/dL (text says mg/kg, likely typo), long-standing diabetes (>10 years on insulin), moderate/severe porto-pulmonary hypertension or hepatopulmonary syndrome, Budd Chiari syndrome, re-transplantation, massive blood transfusion, and graft/weight ratio > 1.4 or < 0.8.
04
Endpoints
Primary
Incidence of postreperfusion syndrome
Secondary
Arrhythmia
Ischemia
Liver graft function
Acute kidney injury
3-month survival
one-year survival
Beyond the preview
Go deeper on NCT03773276.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773276.